Guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (6)
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Quality standards
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (2)
- New quality standards in the last 6 months (0)
- Updated quality standards in the last 6 months (0)
- In development quality standards (0)
Guidance by programme
-
NICE guidelines (6)
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance (72)
Reviews the clinical and cost-effectiveness of new treatments.
-
Diagnostics guidance (1)
Review new diagnostic technologies for adoption in the NHS.
-
Highly specialised technologies guidance (3)
Review clinical and cost-effectiveness of specialised treatments.
-
Medical technologies guidance (1)
Reviews new medical devices for adoption in the NHS.
Advice by programme
-
Evidence summaries (3)
Review the best available evidence for selected medicines.
-
Medtech innovation briefings (3)
Review the evidence and likely costs of medical devices and technologies.
Products being developed or updated
-
In consultation (2)
Guidance and quality standards open for consultation.
-
In development (19)
Guidance, quality standards and advice being developed.
-
Awaiting development (20)
Guidance and quality standards awaiting development.
-
Topic selection (6)
Guidance in topic selection.
Get involved
Comment on guidance in development
Current guidance in consultation
News on this topic
NICE recommends first treatment in two decades for sickle cell disease
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
Putting guidance into practice
Shared learning
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 1 of 1 shared learning examples for this topic: